Sort by
Refine Your Search
-
Listed
-
Program
-
Field
-
), Nordic EMBL Partnership for Molecular Medicine The Computational Biology & Gene Regulation group led by Anthony Mathelier at the NCMM, a part of the Nordic EMBL Partnership for Molecular Medicine, is
-
for monogenic immune diseases. We use high-throughput biology techniques to optimize, develop and understand the CRISPR-Cas9 system that forms the base of the platform, and develop and implement methods
-
the NORPOD program. The work focuses on building a gene editing platform that can be used to correct patient-specific mutations in ex vivo cell therapies for monogenic immune diseases. We use high-throughput
-
a gene editing platform that can be used to correct patient-specific mutations in ex vivo cell therapies for monogenic immune diseases. We use high-throughput biology techniques to optimize, develop
-
clinical setting. We will use the gene editing technologies for the benefit of the patients in the Nordic hospitals. NORPOD is a collaborative postdoctoral program of the Nordic EMBL Partnership
-
on building a gene editing platform that can be used to correct patient-specific mutations in ex vivo cell therapies for monogenic immune diseases. We use high-throughput biology techniques to optimize
-
period of employment. Formal regulations Please see the guidelines and regulations for appointments to Postdoctoral fellowships at the University of Oslo. No one can be appointed for more than one
-
Marieke Kuijjer at the Centre for Molecular Medicine Norway (NCMM), UiO, Nordic EMBL partner (see https://www.kuijjerlab.org / for more information). The successful candidate will be embedded in both groups
-
at the Centre for Molecular Medicine (NCMM, Nordic EMBL partnership institute), Faculty of Medicine, University of Oslo, Norway. We are seeking a highly motivated and talented experimental wet-lab scientist